Search

Author/Creator Abada, Paolo B

1. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 2 (February 2019)

Authors:
Zhu, Andrew X; Kang, Yoon-Koo; Yen, Chia-Jui; Finn, Richard S; Galle, Peter R; Llovet, Josep M; Assenat, Eric; Brandi, Giovanni; Pracht, Marc; Lim, Ho Yeong; Rau, Kun-Ming; Motomura, Kenta; Ohno, Izumi; Merle, Philippe; Daniele, Bruno; Shin, Dong Bok; Gerken, Guido; Borg, Christophe; Hiriart, Jea...
Journal:
Lancet oncology
Issue:
Volume 20:Issue 2(2019)
Page Start:
282
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Issue 7 (July 2015)

Authors:
Zhu, Andrew X; Park, Joon Oh; Ryoo, Baek-Yeol; Yen, Chia-Jui; Poon, Ronnie; Pastorelli, Davide; Blanc, Jean-Frederic; Chung, Hyun Cheol; Baron, Ari D; Pfiffer, Tulio Eduardo Flesch; Okusaka, Takuji; Kubackova, Katerina; Trojan, Jorg; Sastre, Javier; Chau, Ian; Chang, Shao-Chun; Abada, Paolo B; Ya...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 7(2015:Jul.)
Page Start:
859
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search